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Background: Prostaglandin E2 (PGE2)–PGE2 receptor subtype 4 (EP4) signaling is known to 
modulate the inflammation process. Several studies have demonstrated the potential utility of 
EP4-selective agonists for the management of autoimmune and inflammatory diseases. In the present 
study, we assessed the immunosuppressive efficacy of a selective EP4 agonist in experimental rat 
organ transplantation models. 
Methods: A selective EP4 agonist (CAY10580) was continuously injected by subcutaneous insertion 
of infuser pumps into recipient rats that underwent heterotopic heart and small bowel transplantation. 
Results: The administration of EP4 agonist significantly delayed cardiac allograft survival and 
delayed the onset of rejection in both the cardiac and intestinal allografts. Expression of 
pro-inflammatory cytokines of interferon-γ (IFN-γ) was suppressed by the treatment compared with 
the vehicle-treated group. Furthermore, the expression of suppressor of cytokine signaling-1 
(SOCS-1), a known intracellular regulation factor of IFN-γ, was also down-regulated compared with 
the control group. 
Conclusions: These results suggest that selective EP4 agonists represent a novel class of 
immune-modulator drugs that could be useful for the management of acute allogeneic rejection. 
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Despite advances in surgical procedures and immunosuppressive agents that have allowed 
for the establishment of organ transplantation for treatment of life-threatening diseases, acute and 
chronic rejection remains a major problem in this field. Current immunosuppressive regimens 
comprising several agents, such as calcineurin inhibitors (CNIs), antimetabolites, steroids, and 
antibody drugs, accomplish better short-term outcomes. However, long-term administration of 
immunosuppressive agents, especially CNIs, leads to an increased risk of unfavorable side effects 
such as hypertension, nephrotoxicity, neurotoxicity, post-transplant malignancy, and metabolic 
deterioration (1). It is therefore highly desirable to identify new immunosuppressants with novel 
mechanisms and alternative strategies that have the potential to replace or minimize CNIs. 
Prostaglandin E2 (PGE2) is produced during inflammatory responses and mediates a variety 
of both innate and adaptive immune responses through PGE2 receptor subtypes (EP) 1–4, which 
have distinct and potentially antagonistic signaling cascades (2). Recent studies show that 
PGE2–EP4 signaling is an important regulator of the immune response, and EP4 has emerged as an 
alternative therapeutic target for several autoimmune and inflammatory diseases (3-5). Our group 
also reported that immune-mediated mouse liver injuries are ameliorated by the administration of 
PGE2 and selective EP4 agonists caused by suppression of interferon (INF)-γ production in natural 
killer T cells (6). Moreover, studies involving murine colitis models of inflammatory bowel diseases 
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revealed that EP4 works to suppress innate immunity and facilitate the proliferation of regulatory T 
cells (7). Selective EP4 agonists have also been reported to inhibit the production of chemokines and 
cytotoxic cytokines from immune cells, which suppress helper T1 cell differentiation, and promote 
epithelial cell survival and growth by activating anti-apoptotic and proliferative cellular signaling 
pathways (3,8,9).  
Consistent with those findings, PGE2–EP4 signaling will be an alternative target to protect 
the alloimmune response after organ transplantation. However, the role of selective EP4 agonist 
administration to modulate immunological responses remains unresolved with the exception of a few 
studies of a murine cardiac transplantation model (10,11). The objective of this study was to 
investigate the possibility that a selective EP4 agonist protects against alloimmune rejection in rat 
organ transplantation models including heart and small bowel transplants based on the fact that 




Materials and Methods 
Animals 
All animal care and experimental protocols used in this study were approved by the local 
ethics committee of Kyoto University, Institute of Frontier Medical Sciences. The experiments were 
conducted using male Brown Norway (BN) rats (RT-1
n
) and Lewis (LEW) rats (RT-1
l
) weighing 200 
to 300 g and 7 to 10 weeks old, obtained from SLC (Kyoto, Japan).  
Heart and small bowel transplantation; treatment regimens 
For evaluation of the immunosuppressive effects of EP4 agonist, two types of rat organ 
transplantation were performed: heterotopic heart-lung and heterotopic small bowel transplantation. 
Intra-abdominal heterotopic heart-lung transplantation with one artery anastomosis method was 
performed as described by Muranaka et al. (12) with some modification. LEW rat heart-lung was 
heterotopically transplanted into BN rats or synergistically from LEW to LEW rats. After the donor 
rats were anesthetized and the chest wall was opened, the azygos vein with the left superior and right 
superior venae cavae was ligated and divided, followed by ligation and division of the inferior vena 
cava. The ascending aorta was dissected and transected under the portion of the left common carotid 
artery. An end-to-side anastomosis was performed with 9-0 nylon between the donor’s ascending 
aorta and the recipient’s aorta. The beating of the cardiac graft was monitored by daily palpitation 
through the recipient’s abdominal wall. Rejection was defined as the time of cessation of graft 
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beating as confirmed by direct inspection (n=8, per each group), and histological examination of 
cardiac grafts rejection were evaluated 7 days after transplantation from another sets of experimental 
groups (n=6, per each group). Recipient animals were continuously administered an EP4 agonist of 
CAY10580 (100 μg/kg/day; Sigma-Aldrich, St. Louis, MO, USA) or control vehicle (10% 
DMSO-PBS) between days 0 and 14 after transplantation via a subcutaneously inserted infuser 
pump (ALZET osmotic pump, Model 2002; Cupertino, CA, USA) (n = 8 each).  
Heterotopic small bowel transplantation was performed according to the modified methodology 
described by Monchik and Russel (13). A BN rat small intestine was heterotopically transplanted in a 
LEW rat. After the donor rats were anesthetized, an approximately 30-cm intestinal segment was 
removed from the donor using the superior mesenteric artery with the aortic cuff and portal vein as a 
vascular pedicle. An end-to-side anastomosis was performed with 9-0 nylon between the donor’s 
aortic cuff and the recipient’s aorta and between the donor’s portal vein and the recipient’s infrarenal 
vena cava. A Thiry-Vella loop was placed in the right abdominal flank. Acute rejection was 
evaluated by histological examination 6 days after transplantation. Recipient animals were 
continuously administered an EP4 agonist of CAY10580 (100 μg/kg/day; Sigma-Aldrich) or control 
vehicle (10% DMSO-PBS) between days 0 and 14 after transplantation via a subcutaneously 
inserted infuser pump (ALZET Model 2002) (n = 5 each). An additional control group comprised 
BN rats that were neither transplanted nor exposed to any procedure (n = 5). 
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Analysis of plasma creatine phosphokinase  
7days after heart-lung transplantation, blood samples were obtained via inferior vena cava 
puncture, immediately centrifuged at 1500 g for 5 min, and stored at -80°C until analysis. Plasma 
creatine phosphokinase activities were measured using a standard clinical automatic analyzer. 
Histologic analysis 
Each excised graft was immediately fixed in 10% formaldehyde solution, embedded in paraffin, 
sectioned at 5-μm thickness, mounted on glass slides, and deparaffinized. For histological analysis, 
slices were stained using hematoxylin-eosin standard techniques and examined in cross sections at 
40× and 100× magnifications under a microscope. The area ratio of myocardial cell infiltration 
(affected/entire area) was calculated with NIH Image J 1.44 imaging software (NIH, Bethesda, MD, 
USA). The grading of acute rejection of intestinal grafts was performed as proposed and established 
by Wu et al. (19). To observe intestinal Paneth and goblet cells, Alcian blue and periodic acid-Schiff 
combined staining was used. In brief, following incubation in 1% Alcian blue for 15 minutes, 
sections were incubated in 0.5% periodic acid solution for 5 minutes and in Schiff reagent for 15 
minutes. Alcian blue-positive Paneth cells and periodic acid-Schiff–positive goblet cells were 
counted over the size of a 0.5-mm grid at original magnification and at 100× in 10 fields randomly 




Immunohistochemical studies of heart and intestinal tissues were performed on formalin-fixed, 
paraffin-embedded sections. These sections were deparaffinized before staining by xylene extraction, 
followed by extraction with ethanol and water. CD3 (1:1500; Dako, Glostrup, Denmark) and 
MAC387 (1:400; Novocastra, Newcastle, UK) antibodies were separately added onto the slides and 
incubated for 1 hour at room temperature. Tissue sections were then sequentially incubated with goat 
anti-rabbit biotinylated IgG and ExtrAvidin-conjugated horseradish peroxidase. Staining was 
developed with diaminobenzidine substrate, and nuclei were counterstained with hematoxylin. 
Images were obtained using a DP-2 digital camera connected to an AX 80 light 
microscope (both from Olympus, Tokyo, Japan). Settings for image acquisition were identical for 
control and experimental tissues. Four ocular fields per section were captured, and a threshold 
optical density that best discriminated staining from the background was obtained using NIH Image 
J 1.44 imaging software (NIH, Bethesda, MD, USA). The total pixel intensity was determined and 
data were expressed as optical density using a counting grid at 40× magnification. 
Extraction of RNA and real-time quantitative polymerase chain reaction analysis 
Total RNA was purified from heart and intestinal tissues using the RNAeasy Plus Mini kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s protocol. Complimentary DNA (cDNA) 
was generated from 1 ng of whole RNA using a SuperScript VILO cDNA synthesis kit (Invitrogen, 
Carlsbad, CA, USA). cDNA was analyzed for content using a SYBR-Green based quantitative 
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fluorescent PCR method (Applied Biosystems, Foster City, CA, USA). Fluorescence was detected 
with the Applied Biosystems 7500 Real-time PCR system (Applied Biosystems). Primers from 
Roche Universal ProbeLibrary (Roche Diagnostics, Basel, Switzerland) and Shen et al. (20), 
summarized in Table 1, were used. The following PCR conditions were used: 95°C for 15 min, 
followed by 40 cycles at 94°C for 15 sec, 60°C for 30 sec, and 72°C for 1 min, followed by 72°C for 
a final 10 min. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a housekeeping 













, and the final data were derived from 2
-ΔΔCt
. 
Plasma cytokine quantification by ELISA 
Sandwich ELISA for rat plasma IFN-γ and IL-6 were performed using ELISA kits 
(Qiagen, Dusseldorf, Germany) according to the manufacturer’s protocol. 
Statistical analysis 
Data are presented as means ± standard error of the mean. Comparisons between two 
groups were carried out using a two-tailed Student’s t test and between multiple groups using 
one-way analysis of variance with Tukey’s test of significance between individual groups. Survival 
data were plotted using Kaplan-Meier methods and analyzed using the log-rank test. Differences 





Treatment with selective EP4 agonist prohibited acute rejection and prolonged graft survival after 
cardiac transplantation 
The administration of a selective EP4 agonist of CAY10580 significantly prolonged cardiac 
allograft survival compared with vehicle-treated controls (n = 8, 11.0 ± 1.0 vs 8.0 ± 1.0 days, p < 
0.01, by log-rank test) (Fig. 1A). The serum creatine phosphokinase concentration was significantly 
decreased in the CAY10580-treated group compared with the vehicle-treated controls (n = 8, p < 
0.01) (Fig. 1B). In the vehicle-treated controls, cardiac allografts were macroscopically enlarged (Fig. 
1C), and myocardial cell infiltration was observed on day 7 (n = 6, 20.1% ± 7.8%). However, the 
CAY10580-treated group showed attenuation of the development of myocardial cell infiltration on 
day 7 (n = 6, 7.3% ± 2.5%, p < 0.01) (Fig. 1D, E). These results suggest that EP4 agonist treatment 
ameliorates acute cardiac allorejection. 
Treatment with selective EP4 agonist attenuated acute rejection in intestinal allografts 
Graft intestinal tissues were obtained on day 6 in all groups. Histopathological evaluation 
revealed that the intestinal graft in the vehicle-treated allogeneic group showed severe acute 
rejection; conversely, the graft in the CAY10580-treated group showed moderate acute rejection 
(Fig. 2A, a-f). Alcian blue and periodic acid-Schiff staining revealed that epithelial mucosal 
destruction was significantly attenuated in the EP4-treated group (n = 5, p < 0.05) (Fig. 2A, g-i). 
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These findings in the EP4 agonist-treated group indicate moderate acute rejection of the intestinal 
graft. 
Treatment with selective EP4 agonist attenuated infiltration of inflammatory cells and inhibited 
apoptotic reaction in allografts 
Immunohistological analysis revealed that vehicle-treated cardiac (Fig. 3A) and intestinal 
grafts (Fig. 3B) showed CD3 (marker for pan-T cells)-positive cells and MAC387 (marker for a 
subset of reactive/infiltrating monocytes/macrophages)-positive cells in the infiltrated area. However, 
EP4 treatment significantly diminished infiltration of these positive cells (p < 0.05). These results 
suggest that EP4 treatment suppresses lymphoplasmacytic infiltration in both cardiac and intestinal 
allografts and apoptotic reaction of epithelial cells in intestinal allografts. 
Selective EP4 agonist administration altered pro-inflammatory cytokine mRNA expression 
The mRNA expression levels of pro-inflammatory (interleukin [IL]-1β, IL-2, IL-6, tumor 
necrosis factor-α, and IFN-γ) and anti-inflammatory (IL-10 and transforming growth factor-β1) 
cytokines in the cardiac and intestinal grafts were estimated by quantitative RT-PCR. EP4 treatment 
inhibited mRNA expression of IL-6 and/or IFN-γ compared with the vehicle-treated cardiac (Fig. 
4A) and intestinal (Fig. 4B) allografts, but significant differences in mRNA expression levels of 
anti-inflammatory cytokines between the two groups were not observed (*p < 0.05, **p < 0.01).  
IFN-γ expression was inhibited by selective EP4 agonist administration in the intestinal allografts 
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Because the mRNA expressions of pro-inflammatory cytokines were down-regulated by EP4 
treatment, we estimated the plasma concentrations of IFN-γ and IL-6 in the intestinal transplantation 
groups. EP4 treatment significantly decreased plasma IFN-γ levels (p < 0.05) (Fig. 5A). Furthermore, 
because IFN-γ and IL-6 are responsible for induction of suppressor of cytokine signaling (SOCS)-1 
and SOCS-3, respectively, we investigated these mRNA expressions in allografts and plasma levels 
of IFN-γ and IL-6. The EP4-treated group showed significant suppression of SOCS-1 expression (p 
< 0.05) (Fig. 5B). These results suggest that the allorejection suppression effects of EP4 treatment 




In this investigation, we demonstrated that continuous subcutaneous injection of EP4 
agonist ameliorated acute rejection in both rat heart and small bowel transplantation models. 
Immunohistochemical analysis revealed that EP4 agonist significantly reduced lymphoplasmacytic 
infiltration in allografts and suppressed intestinal epithelial cell apoptosis. These activities were 
accompanied by a decrease in the expression of pro-inflammatory cytokines of IFN-γ, and 
quantitative RT-PCR analysis revealed that SOCS-1, which is a intracellular regulation factor 
responsible for IFN-γ, was also significantly down-regulated by the EP4 treatment. These findings 
imply that the reduced development of transplant allogeneic acute rejection by EP4 agonist 
administration is related to the attenuation of pro-inflammatory cytokine of IFN-γ.  
Several studies and our previous investigations have demonstrated that EP4-selective agonists 
possess anti-inflammatory properties, and previous studies revealed that exogenous PGE2 
administration delayed the onset of rejection in experimental rat transplantation models (16-19). 
PGE2 has EP1–4 receptors, and PGE2–EP2/4 signaling has been reported those immunosuppressive 
reaction of PGE2. According to these findings and the findings of a few recent reports suggesting 
that EP4 receptor activation prolonged cardiac allograft survival in murine transplantation models, 
we considered that EP4-selective agonists represent a novel class of immune-modulator drugs that 
could be useful for the management of not only autoimmune inflammatory diseases, but also acute 
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rejection after allogeneic transplantation. To the best of our knowledge, this study was the first to 
evaluate the effects of EP4 agonist as an immune suppressor in rat heart and small bowel 
transplantation models. 
Although the anti-inflammatory mechanisms of PGE2–EP4 signaling have not been clearly 
established, many papers have suggested that PGE2–EP4 signaling modulates pro- and 
anti-inflammatory cytokine expressions and is correlated with T-lymphocyte differentiation. In our 
previous mice studies and in the present study, suppression of IFN-γ expression was consistently 
observed with the administration of EP4 agonist. Therefore, we focused on IFN-γ–Janus kinase 
(JAK) and the signal transducer and activator of transcription (STAT) signaling pathways, which 
both play important roles in the transcriptional control of pro-inflammatory cytokines. Chinen et al. 
recently reported that SOCS–STAT signaling was activated by PGE2–EP4 signals and that this 
signaling suppressed promotion of the inflammatory process in mice colitis models (19). In the 
present study, we could not determine the presence of a relationship between the SOCS–STAT-1 
activation (data not shown), but its possibility will be considered in further investigations.  
As discussed above, several studies have recognized that PGE2–EP4 signaling is an 
important regulator of the immune response. Therefore, a human clinical trial of an EP4 agonist for 
inflammatory bowel disease treatment was recently conducted and showed promising therapeutic 
effects (20). However, it was also reported that systemic exposure of EP4 agonists caused some side 
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effects, such as diarrhea and hypotension, because PGE2–EP4 signals also play significant 
physiological roles in several organs other than immunological reactions. Further investigations, not 
only of the biological mechanisms but also of the pharmacological and pharmaceutical aspects of the 
ability of EP4 agonists to minimize unwanted physiological effects, are desirable for evaluation of 
clinical applications. 
In summary, the present results show for the first time that systemic administration of an 
EP4 agonist can effectively suppress acute rejection in rat heart and small bowel transplantation 
models. EP4 agonists may be a potential therapeutic candidate for combination with CNIs following 
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Legends for Figures 
Figure 1. Selective EP4 agonist of CAY10580 (EP4) treatment attenuated allogeneic rejection in the 
rat heart-lung transplantation model. (A) Survival of cardiac allografts (Lewis [LEW] to Brown 
Norway [BN]). Rats treated with EP4 (solid line) showed prolonged allograft survival compared 
with the vehicle-treated rats (dotted line) (n = 8, 11.0 ± 1.0 vs 8.0 ± 1.0 days, p < 0.01, by log-rank 
test). (B) The serum creatine phosphokinase concentration was significantly decreased in the 
EP4-treated group compared with the vehicle-treated controls (n = 8, 140 ± 53 vs 386 ± 107 IU/L, p 
< 0.05). (C) Representative gross findings and (D,a-f) histologic findings (hematoxylin-eosin 
staining) of cardiac allografts on day 7. In the vehicle-treated controls, cardiac allografts were 
macroscopically enlarged, and myocardial cell infiltration was observed (D,b,e, n = 6, 20.1% ± 
7.8%). However, the EP4-treated group showed attenuation of the development of myocardial cell 
infiltration on day 7 (D,c,f, n = 6, 7.3% ± 2.5%, p < 0.01). Scale bars = 200 μm. *p < 0.05, **p < 
0.01. 
Figure 2. Selective EP4 agonist of CAY10580 (EP4) treatment also attenuated allogenic rejection 
in the rat small bowel transplantation model. Graft intestinal tissues were obtained on day 6 in all 
groups, and representative histological sections were examined microscopically after 
hematoxylin-eosin and Alcian blue and periodic acid-Schiff staining. (A, a-f) The intestinal graft in 
the vehicle-treated allogeneic group showed severe acute rejection; in contrast, the graft in the 
EP4-treated group showed moderate acute rejection. (A, g-i) Alcian blue and periodic 
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acid-Schiff–positive epithelial mucosal cell counts were significantly different between the 
vehicle-treated and EP4-treated groups (n =5, 7 ± 3 cells vs 146 ± 22 cells per 0.5-mm square; *p < 
0.05, **p < 0.01). Scale bars = 300 μm (a-c). Scale bars = 200 μm (d-i). 
Figure 3. Representative CD3 and MAC387 immunohistochemistry of cardiac and intestinal 
allografts. (A) Vehicle-treated cardiac allografts showed many CD3- and MAC387-positive cells in 
infiltrated areas. However, EP4 treatment attenuated infiltration of these positive cells (n=6, *p < 
0.05. Scale bars = 200 μm) . (B) In intestinal allografts, CD3-positive cells remarkably infiltrated the 
submucosal area in vehicle-treated allografts; in contrast, this infiltration of positive cells was 
attenuated by EP4 treatment. Significant differences between the number of MAC387-positive cells 
in the vehicle-treated and EP4-treated groups were not observed (n=5, *p < 0.05. Scale bars = 200 
μm). 
Figure 4. Expression of mRNA levels of pro-inflammatory and anti-inflammatory cytokines in the 
(A) cardiac (n=6) and (B) intestinal allografts (n=5) as estimated by quantitative RT-PCR. EP4 
treatment significantly inhibited mRNA expressions of IL-6 and IFN-γ compared with the 
vehicle-treated cardiac allografts and significantly inhibited mRNA expression of IFN-γ compared 
with the vehicle-treated intestinal allografts (*p < 0.05).  
Figure 5. EP4 treatment suppressed the IFN-γ signaling pathway and nuclear-factor (NF)-κB 
activation in the intestinal allografts. (A) Plasma concentrations of IFN-γ and IL-6 in the intestinal 
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transplantation groups were estimated by ELISA. EP4 treatment significantly decreased plasma 
IFN-γ levels (n=5, 610.2 ± 80.1 vs 462.1 ± 22.9 pg/ml, *p < 0.05). (B) Suppressor of cytokine 
signaling (SOCS)-1 and SOCS-3 mRNA expressions in intestinal allografts were measured by 
quantitative real-time PCR. The EP4-treated group showed significantly suppressed SOCS-1 mRNA 





Table 1: Primers used in quantitative real-time PCR analysis 
m RNA Forward Reverse 
IL-1β 5’- TGTGATGAAAGACGGCACAC -3’ 5`- CTTCTTCTTTGGGTATTGTTTGG -3’ 
IL-2 5’- AAACTCCCCATGATGCTCAC -3’ 5’- GAAATTTCCAGCGTCTTCCA -3’ 
IL-6 5’- CCGGAGAGGAGACTTCACAG -3’ 5’- ACAGTGCATCATCGCTGTTC- 3’ 
IL-10 5’- AGTGGAGCAGGTGAAGAATGA-3’ 5’- TCATGGCCTTGTAGACACCTT -3’ 
IFN-γ 5’- TGAAAGCCTAGAAAGTCTGAAGAAC -3’ 5’- CGTGTTACCGTCCTTTTGC -3’ 
TNF-α 5’- TGAACTTCGGGGTGATCG -3’ 5’- GGGCTTGTCACTCGAGTTTT -3’ 
TGF-β1 5’- GCAACACGTAGAACTCTACCAGAA -3’ 5’- CAGCCACTCAGGCGTATCA -3’ 
SOCS-1 5’- TGGTAGCACGTAACCAGGTG-3’ 5’- GAAGGTGCGGAAGTGAGTGT-3’ 
SOCS-3 5’- CCTTTGAGGTTCAGGAGCAG-3’ 5’- CGTTGACAGTCTTCCGACAA-3’ 
GAPDH 5’- AGCTGGTCATCAATGGGAAA -3’ 5’- ATTTGATGTTAGCGGGATCG -3’ 
IL, interleukin; IFN-γ, interferon-γ; TNF-α, tumor necrosis factor-α; TGF-β1, transforming growth 
factor-β1; SOCS, suppressor of cytokine signaling; GAPDH, glyceraldehyde-3-phosphate 
dehydrogenase 
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